Coalition Tensions Stall Gene Technology Bill Reform
Controversial legislation to end 30-year ban on genetic engineering outside labs hits parliamentary roadblock
**WELLINGTON** — The Government’s Gene Technology Bill, which would end an effective three-decade ban on the use of genetic technologies outside the laboratory, has stalled ahead of its second reading amid coalition tensions and unresolved concerns from political parties.
The bill would replace the Hazardous Substances and New Organisms Act 1996 (HSNO Act), widely regarded as one of the strictest regulatory regimes in the OECD, with a risk-tiered system modelled on Australia’s Gene Technology Act 2000. It would establish an independent Gene Technology Regulator within the Environmental Protection Authority, supported by a Technical Advisory Committee and a Māori Advisory Committee.
Political parties have been negotiating the bill’s provisions, but a date for second reading remains unconfirmed, with the legislation stalled before the November general election.
Why reform matters
The current HSNO framework has effectively prevented the release of genetically modified organisms into New Zealand’s environment since 1998. Only three GMOs have been released without conditions in that 28-year period. Scientists and industry groups argue the restrictions have created a “chilling effect,” forcing promising domestic research projects to be carried out overseas in less restrictive jurisdictions.
The Ministry of Business, Innovation and Employment (MBIE) has identified potential benefits including new therapies for genetic diseases and cancer, agricultural feed grasses that could reduce animal emissions, and crops more resilient to pests and climate pressures. New Zealand’s biotech sector generated $2.7 billion in revenue in 2020, despite operating under what the MBIE describes as an “effective ban on non-medical GMOs.”
Māori perspectives
The bill includes provision for a Māori Advisory Committee (MAC), reflecting the importance of tikanga Māori and kaitiakitanga (guardianship) in environmental decision-making. However, the integration of mātauranga Māori (Māori knowledge) into gene technology regulation remains a point of discussion among iwi and hapū.
Debbie Ngarewa-Packer, co-leader of Te Pāti Māori, has previously voiced concerns about the pace of reform and the need for genuine partnership with Māori communities on decisions that affect the natural environment.
Critics, including the advocacy group Protect NZ Food, argue the bill risks undermining New Zealand’s GE-free food reputation and consumer choice. They point to polling showing only 14 per cent of the public supports easing GMO regulations.
Coalition politics
Sources close to the negotiations suggest the stalling reflects a lack of majority support to advance the bill to second reading. The ruling coalition’s internal dynamics, combined with election-year sensitivities around food safety and environmental protection, have complicated the pathway forward.
The Health Committee has examined the bill and recommended by majority that it proceed, with unanimous support for its amendments. But translating committee support into parliamentary progress has proven difficult.
International context
New Zealand’s major trading partners, including Australia, Japan, the United States, and the European Union, have moved to reduce restrictions on gene technologies. The MBIE argues that reforming New Zealand’s regime now would position the country’s scientists and businesses to take advantage of significant opportunities in future biotech markets.
The bill’s fate before the November election remains uncertain. Political commentators suggest that if it is not resolved in the current parliamentary term, it could be reintroduced by whichever government forms after the election.
—
*By Moana Kahui | Wellington | 13 May 2026*
